Radnostix, Inc.

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services in the United States and internationally. It operates through five segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. It offers flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot and pen point markers, and various specialty design items. The Cobalt Products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy and various industrial applications; and recycles expended cobalt sources. The Radiochemical Products segment produces and distributes various isotopically pure radiochemicals and sodium iodide I-131 generic drug product for medical, industrial, and research applications. The Radiological Services segment provides flood source disposal and gemstones processing services. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. It sells its products directly to end users and distributors. International Isotopes Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.

Radnostix, Inc. trades as INIS on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $13.07M of revenue and -$908,000 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Radnostix, Inc. can be compared against peers such as Decibel Cannabis Company Inc., BellRock Brands Inc., Earth Science Tech, Inc., Flower One Holdings Inc., Medexus Pharmaceuticals Inc., 1CM Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $37.04M, beta of 1.17, and return on equity of -24.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

INIS currently shows total debt of $4.84T and beta of 1.17. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://radnostix.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.